Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|September 3, 2026

The BioPharm Brief: Setbacks, Submissions, and a $1.3B Deal

Listen
0:00 / 0:00

Today’s BioPharm Brief leads with a late-stage clinical setback for Ultragenyx, a major gene therapy filing from uniQure, and a billion-dollar oncology licensing deal between HUTCHMED and GSK.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here’s what’s making headlines today.

Ultragenyx is facing a major setback in Angelman syndrome. The company’s apazunersen failed to meet the primary endpoint in the Phase 3 Aspire study, which evaluated the antisense oligonucleotide in children and adolescents with the rare neurodevelopmental disorder. The trial also missed a key secondary endpoint. The result is a significant blow to a program that had been an important part of Ultragenyx’s pipeline.

uniQure is moving AMT-130 into the regulatory review process for Huntington’s disease. The company submitted a Biologics License Application to the FDA seeking accelerated approval for ifezuntirgene inilparvovec, formerly known as AMT-130. uniQure also submitted a Marketing Authorisation Application to the UK’s Medicines and Healthcare products Regulatory Agency. The filings mark a major step for the investigational gene therapy, which is designed to address the underlying disease process in Huntington’s disease.

And HUTCHMED has struck a deal with GSK for its KRAS-EGFR therapy HMPL-A830. The agreement gives GSK rights outside Greater China and includes a $110 million upfront payment and up to $1.185 billion in additional development, regulatory, and commercial milestones. HUTCHMED will lead the global Phase 1 program, while GSK will take over subsequent development and commercialization outside the retained territories.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Ultragenyx’s apazunersen failed to meet the primary and key secondary endpoints in phase 3 testing for Angelman syndrome.
  • uniQure has submitted US and UK regulatory applications for AMT-130, its investigational gene therapy for Huntington’s disease.
  • HUTCHMED licensed its KRAS-EGFR antibody-drug conjugate HMPL-A830 to GSK in a deal worth up to $1.295 billion.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more